Evaluation of a peptide ELISA for the detection of rituximab in serum

Journal of Immunological Methods

Volumn 325, Issue 1-2, 2007, Pages 127-139

  Blasco, H ^a   Lalmanach, G ^a   Godat, E ^a   Maurel, M C ^b   Canepa, S ^b   Belghazi, M ^b   Paintaud, G ^a   Degenne, D ^a   Chatelut, E ^c   Cartron, G ^a   Le Guellec, C ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b UMR85 PHYSIOLOGIE DE LA REPRODUCTION ET DES COMPORTEMENTS   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Anti idiotype; CD20; ELISA; Peptide; Rituximab; Surface plasmon resonance

Indexed keywords

BIOTIN; BOVINE SERUM ALBUMIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2A4; PEPTIDE DERIVATIVE; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CONJUGATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HUMAN; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MASS SPECTROMETRY; MICE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; SERUM ALBUMIN, BOVINE; SURFACE PLASMON RESONANCE;

BOVINAE; MUS;

EID: 34547850227     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2007.06.011     Document Type: Article

References (32)

1. Adamson P.J., Zola H., Nicholson I.C., Pilkington G., and Hohmann A. Antibody against CD20 in patients with B cell malignancy. Leuk. Res. 25 (2001) 1047
2. Berinstein N.L., Grillo-Lopez A.J., White C.A., Bence-Bruckler I., Maloney D., Czuczman M., Green D., Rosenberg J., McLaughlin P., and Shen D. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 9 (1998) 995
3. Beum P.V., Kennedy A.D., and Taylor R.P. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Methods 289 (2004) 97
4. Binder M., Otto F., Mertelsmann R., Veelken H., and Trepel M. The epitope recognized by rituximab. Blood 16 (2006) 16
5. Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Park K., Pearson M., Waselenko J.K., Ling G., Grever M.R., Grillo-Lopez A.J., Rosenberg J., Kunkel L., and Flinn I.W. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19 (2001) 2153
6. Cragg M.S., Bayne M.B., Tutt A.L., French R.R., Beers S., Glennie M.J., and Illidge T.M. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 104 (2004) 2540 (Electronic publication 2004 Jun 22)
7. Demeule B., Gurny R., and Arvinte T. Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates. Eur. J. Pharm. Biopharm. 62 (2006) 121
8. DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., and Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20 (2003) 1885
9. Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., Botto M., Introna M., and Golay J. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171 (2003) 1581
10. Ernst J.A., Li H., Kim H.S., Nakamura G.R., Yansura D.G., and Vandlen R.L. Isolation and characterization of the B-cell marker CD20. Biochemistry 44 (2005) 15150
11. Findlay J.W., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., and Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21 (2000) 1249
12. Giles F.J., Vose J.M., Do K.A., Johnson M.M., Manshouri T., Bociek G., Bierman P.J., O'Brien S.M., Keating M.J., Kantarjian H.M., Armitage J.O., and Albitar M. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br. J. Haematol. 123 (2003) 850
13. Godat E., Lecaille F., Desmazes C., Duchene S., Weidauer E., Saftig P., Bromme D., Vandier C., and Lalmanach G. Cathepsin K: a cysteine protease with unique kinin-degrading properties. Biochem. J. 383 (2004) 501
14. Gorman C., Leandro M., and Isenberg D. B cell depletion in autoimmune disease. Arthritis Res. Ther. 5 (2003) 17 (Electronic publication 2003 Oct 2)
15. Hong K., Presta L.G., Lu Y., Penn A., Adams C., Chuntharapai A., Yang J., Wong W.L., and Meng Y.G. Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J. Immunol. Methods 294 (2004) 189 (Electronic publication 2004 Oct 6)
16. Iacona I., Lazzarino M., Avanzini M.A., Rupolo M., Arcaini L., Astori C., Lunghi F., Orlandi E., Morra E., Zagonel V., and Regazzi M.B. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther. Drug Monit. 22 (2000) 295
17. Maloney D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A., and Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84 (1994) 2457
18. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., White C.A., Liles T.M., Royston I., Varns C., Rosenberg J., and Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15 (1997) 3266
19. Mangel J., Buckstein R., Imrie K., Spaner D., Franssen E., Pavlin P., Boudreau A., Pennell N., Combs D., and Berinstein N.L. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Ann. Oncol. 14 (2003) 758
20. Manshouri T., Do K.A., Wang X., Giles F.J., O'Brien S.M., Saffer H., Thomas D., Jilani I., Kantarjian H.M., Keating M.J., and Albitar M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101 (2003) 2507 (Electronic publication 2002 Nov 21)
21. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., Heyman M.R., Bence-Bruckler I., White C.A., Cabanillas F., Jain V., Ho A.D., Lister J., Wey K., Shen D., and Dallaire B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16 (1998) 2825
22. Pabbisetty K.B., Yue X., Li C., Himanen J.P., Zhou R., Nikolov D.B., and Hu L. Kinetic analysis of the binding of monomeric and dimeric ephrins to Eph receptors: correlation to function in a growth cone collapse assay. Protein Sci. 16 (2007) 355
23. Perosa F., Favoino E., Caragnano M.A., and Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 107 (2006) 1070 (Electronic publication 2005 Oct 13)
24. Polyak M.J., and Deans J.P. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99 (2002) 3256
25. Ryan M.E., Webster M.L., and Statler J.D. Adverse effects of intravenous immunoglobulin therapy. Clin. Pediatr. (Phila) 35 (1996) 23
26. Schreiber G. Kinetic studies of protein-protein interactions. Curr. Opin. Struct. Biol. 12 (2002) 41
27. Tedder T.F., and Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15 (1994) 450
28. Tedder T.F., Streuli M., Schlossman S.F., and Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 208
29. Teeling J.L., Mackus W.J., Wiegman L.J., van den Brakel J.H., Beers S.A., French R.R., van Meerten T., Ebeling S., Vink T., Slootstra J.W., Parren P.W., Glennie M.J., and van de Winkel J.G. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177 (2006) 362
30. Tobinai K., Kobayashi Y., Narabayashi M., Ogura M., Kagami Y., Morishima Y., Ohtsu T., Igarashi T., Sasaki Y., Kinoshita T., and Murate T. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann. Oncol. 9 (1998) 527
31. Wang W., Singh S., Zeng D.L., King K., and Nema S. Antibody structure, instability, and formulation. J. Pharm. Sci. 96 (2007) 1
32. Wong S.S. Chemistry of Protein Conjugation and Cross-linking (1991), CRC Press Inc., Boca Raton, FL 147